Objective: To determine the level of knowledge and attitudes regarding AIDS among female commercial sex workers (FCSWs) in Hyderabad City, Sindh, Pakistan.
Design: A cross-sectional survey.
Place And Duration Of Study: Red light area of Hyderabad City, Sindh, Pakistan, from March to July 2004.
Subjects And Methods: A pre-designed questionnaire was administered to see the level of knowledge and attitudes regarding AIDs among FCSWs. In this regard, a total of 61 FCSWs were interviewed after getting informed consent.
Results: Mean age of the FCSWs was 27 years. Majority was uneducated and unmarried. All respondents had heard the word AIDS but no one knew about the word HIV as well as its meaning. All respondents believed that AIDS is a preventable disease and they knew some method of prevention. Television was most common source of knowledge. FCSWs had inadequate knowledge in terms of signs and symptoms and the treatment of disease.
Conclusion: FCSWs of the Hyderabad city had insufficient knowledge and various misconceptions regarding AIDS. Therefore, there is a need for their education and improvement in socioeconomic status. There is also the need of further studies with substantial statistical work to generate more accurate data in this regard.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Elevated Plasma Nitrate Levels in Patients with Acute Coronary Syndrome.
Am J Cardiol
January 2025
Apollo Institute of Medical Science and Research, Apollo Health City, Jubilee Hills, Hyderabad, 500096, India.
Immune complexes-mediated activation of neutrophils in systemic lupus erythematosus is dependent on RNA recognition by toll-like receptor 8.
Front Immunol
January 2025
Division of Rheumatology, University of Washington, Seattle, WA, United States.
Introduction: Neutrophil activation is important in systemic lupus erythematosus (SLE). We previously demonstrated that ribonucleoprotein (RNP) immune complexes (ICs) promoted neutrophil activation in a TLR7/8-dependent manner. However, it remains unclear if this mechanism occurs in patients.
View Article and Find Full Text PDFXalnesiran with or without an Immunomodulator in Chronic Hepatitis B.
N Engl J Med
December 2024
From the Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University (J.H., X.L.), and the State Key Laboratory of Organ Failure Research, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangdong Institute of Hepatology, Nanfang Hospital (J.H.), Guangzhou, the Department of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University (W.Z.), the Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine (Q.X.), Roche Holding (Q.B., E.C.), Roche Research and Development Center (C.C., Y.H.), and Takeda APAC Biopharmaceutical Research and Development (Q.B.), Shanghai, the Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, First Hospital of Jilin University, Changchun (R.H.), the Center of Infectious Diseases, Laboratory of Infectious and Liver Disease, Institute of Infectious Diseases, West China Hospital, Sichuan University, Chengdu (H.T.), and the Department of Medicine and State Key Laboratory of Liver Research, Queen Mary Hospital, University of Hong Kong, Hong Kong (M.-F.Y.) - all in China; the Division of Infectious Diseases, University Hospital Álvaro Cunqueiro, Galicia Sur Health Research Institute, Servizo Galego de Saúde-Universidade de Vigo, Vigo, Spain (L.E.M.A.); the Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital (S.-S.Y.), and the Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, China Medical University (C.-Y.P.), Taichung, the Department of Internal Medicine, Changhua Christian Hospital, Changhua (W.-W.S.), Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung (W.-L.C.), and National Taiwan University Hospital, Taipei (J.-H.K.) - all in Taiwan; the Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, South Korea (D.J.K.); the HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center and the Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok (A.A.), and the Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai (A.L.) - both in Thailand; Université de Paris-Cité, Department of Hepatology, Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Centre de Recherche sur l'Inflammation, INSERM Unité Mixte de Recherche 1149, Paris (T.A.); F. Hoffmann-La Roche, Basel, Switzerland (F. Canducci, M.T.C., F. Chughlay, K.G., N.G., P.K., R.K., M.T.); Roche Products, Welwyn Garden City (S.D., V.P., B.S., R.U., C.W.), and ID Pharma Consultancy, Yelverton (C.W.) - both in the United Kingdom; Enthera Pharmaceuticals, Milan (F. Canducci); Parexel International, Hyderabad, India (A.P.); and the New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand (E.G.).
Background: Xalnesiran, a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome and silences multiple HBV transcripts, may have efficacy, with or without an immunomodulator, in patients with chronic HBV infection.
Methods: We conducted a phase 2, multicenter, randomized, controlled, adaptive, open-label platform trial that included the evaluation of 48 weeks of treatment with xalnesiran at a dose of 100 mg (group 1), xalnesiran at a dose of 200 mg (group 2), xalnesiran at a dose of 200 mg plus 150 mg of ruzotolimod (group 3), xalnesiran at a dose of 200 mg plus 180 μg of pegylated interferon alfa-2a (group 4), or a nucleoside or nucleotide analogue (NA) alone (group 5) in participants with chronic HBV infection who had virologic suppression with NA therapy. The primary efficacy end point was hepatitis B surface antigen (HBsAg) loss (HBsAg level, <0.
Exploration of magnetic zeolite thin film derived from coal fly ash an efficient sorbent: Application to water treatment.
J Environ Manage
January 2025
Faculty of Geology, Geophysics and Environmental Protection, AGH University of Science and Technology, Al. Mickiewicza 30, 30-059, Krakow city, Poland.
Fly ash, produced during coal combustion for energy making, which is recognized as an industrial by-product, could lead to environmental health hazards. Subsequently, fly ash found that an exceptional adsorption performance for the removal of various toxic pollutants, the adsorption capacity of fly ash might be altered by introducing physical/chemical stimulation. Successfully converting fly ash into zeolites not only recovers their disposal difficulties but also transforms unwanted materials into merchandisable products for various industrial applications.
View Article and Find Full Text PDFLung cancer in Asia: the impact of climate change.
EClinicalMedicine
August 2024
Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India.
The escalating global threat of climate change is becoming more evident. The climate crisis intersects with another major challenge: lung cancer. With Asia already bearing half the global cancer burden, the impact of climate-related events on health and on lung cancer care specifically are profound.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!